JP2010529040A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010529040A5 JP2010529040A5 JP2010510531A JP2010510531A JP2010529040A5 JP 2010529040 A5 JP2010529040 A5 JP 2010529040A5 JP 2010510531 A JP2010510531 A JP 2010510531A JP 2010510531 A JP2010510531 A JP 2010510531A JP 2010529040 A5 JP2010529040 A5 JP 2010529040A5
- Authority
- JP
- Japan
- Prior art keywords
- ionic
- poly
- drug
- release
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 34
- 229940079593 drug Drugs 0.000 claims 22
- 239000003814 drug Substances 0.000 claims 22
- 239000000203 mixture Substances 0.000 claims 17
- 239000011347 resin Substances 0.000 claims 16
- 229920005989 resin Polymers 0.000 claims 16
- 238000000034 method Methods 0.000 claims 13
- 230000004888 barrier function Effects 0.000 claims 11
- 238000009792 diffusion process Methods 0.000 claims 11
- 239000013543 active substance Substances 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 9
- 239000002245 particle Substances 0.000 claims 8
- 239000011159 matrix material Substances 0.000 claims 7
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims 6
- 239000003456 ion exchange resin Substances 0.000 claims 6
- 229920003303 ion-exchange polymer Polymers 0.000 claims 6
- 239000007788 liquid Substances 0.000 claims 5
- -1 methoxypropyl Chemical group 0.000 claims 4
- 239000000243 solution Substances 0.000 claims 4
- 239000004793 Polystyrene Substances 0.000 claims 3
- 239000001913 cellulose Substances 0.000 claims 3
- 229920002678 cellulose Polymers 0.000 claims 3
- 235000010980 cellulose Nutrition 0.000 claims 3
- 239000000805 composite resin Substances 0.000 claims 3
- 229910017053 inorganic salt Inorganic materials 0.000 claims 3
- 229920002223 polystyrene Polymers 0.000 claims 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 239000004220 glutamic acid Substances 0.000 claims 2
- 150000002500 ions Chemical class 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 claims 1
- 229920001661 Chitosan Polymers 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 claims 1
- 108010035532 Collagen Proteins 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- 108010010803 Gelatin Proteins 0.000 claims 1
- 239000000020 Nitrocellulose Substances 0.000 claims 1
- 229920001054 Poly(ethylene‐co‐vinyl acetate) Polymers 0.000 claims 1
- 239000004952 Polyamide Substances 0.000 claims 1
- 239000004698 Polyethylene Substances 0.000 claims 1
- 229920000954 Polyglycolide Polymers 0.000 claims 1
- 239000004743 Polypropylene Substances 0.000 claims 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 claims 1
- 229960005261 aspartic acid Drugs 0.000 claims 1
- 230000003190 augmentative effect Effects 0.000 claims 1
- 229920002988 biodegradable polymer Polymers 0.000 claims 1
- 239000004621 biodegradable polymer Substances 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 229920001436 collagen Polymers 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 229920000159 gelatin Polymers 0.000 claims 1
- 239000008273 gelatin Substances 0.000 claims 1
- 235000019322 gelatine Nutrition 0.000 claims 1
- 235000011852 gelatine desserts Nutrition 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 239000004922 lacquer Substances 0.000 claims 1
- 229960000448 lactic acid Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 229920001220 nitrocellulos Polymers 0.000 claims 1
- 230000037074 physically active Effects 0.000 claims 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims 1
- 229920000747 poly(lactic acid) Polymers 0.000 claims 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 1
- 229920000141 poly(maleic anhydride) Polymers 0.000 claims 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 claims 1
- 229920002502 poly(methyl methacrylate-co-methacrylic acid) Polymers 0.000 claims 1
- 229920002647 polyamide Polymers 0.000 claims 1
- 229920001610 polycaprolactone Polymers 0.000 claims 1
- 229920000573 polyethylene Polymers 0.000 claims 1
- 108010050934 polyleucine Proteins 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920000193 polymethacrylate Polymers 0.000 claims 1
- 239000004926 polymethyl methacrylate Substances 0.000 claims 1
- 229920001155 polypropylene Polymers 0.000 claims 1
- 229920002635 polyurethane Polymers 0.000 claims 1
- 239000004814 polyurethane Substances 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 229920000915 polyvinyl chloride Polymers 0.000 claims 1
- 239000004800 polyvinyl chloride Substances 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 239000011342 resin composition Substances 0.000 claims 1
- 239000012266 salt solution Substances 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94095607P | 2007-05-30 | 2007-05-30 | |
| PCT/US2008/065408 WO2008151071A1 (en) | 2007-05-30 | 2008-05-30 | Modifying drug release in suspensions of ionic resin systems |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010529040A JP2010529040A (ja) | 2010-08-26 |
| JP2010529040A5 true JP2010529040A5 (https=) | 2011-07-14 |
Family
ID=40094143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010510531A Pending JP2010529040A (ja) | 2007-05-30 | 2008-05-30 | イオン性樹脂系の懸濁液における薬物放出の調節 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8313770B2 (https=) |
| EP (1) | EP2164631A4 (https=) |
| JP (1) | JP2010529040A (https=) |
| CA (1) | CA2689101C (https=) |
| MX (1) | MX2009013019A (https=) |
| WO (1) | WO2008151071A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102488652B (zh) | 2006-03-16 | 2014-06-18 | 特瑞斯制药股份有限公司 | 含有药物-离子交换树脂复合物的经修饰释放的制剂 |
| JP5425080B2 (ja) | 2007-09-06 | 2014-02-26 | ザ コカ・コーラ カンパニー | 複数の製品形成原料の分注を監視および制御するためのシステムおよび方法 |
| EP2227434A2 (en) | 2007-09-06 | 2010-09-15 | The Coca-Cola Company | Systems and methods for providing portion control programming in a product forming dispenser |
| US20100273822A1 (en) * | 2009-04-22 | 2010-10-28 | William Wayne Howard | Immediate release compositions and methods for delivering drug formulations using strong acid ion exchange resins |
| MX365650B (es) | 2009-12-02 | 2019-06-10 | Adamas Pharmaceuticals Inc | Composiciones de amantadina y metodos para su uso. |
| US8470375B1 (en) | 2010-01-05 | 2013-06-25 | Neos Therapeutics, Lp | Method of formulating and designing liquid drug suspensions containing ion exchange resin particles |
| US20130230587A1 (en) * | 2010-11-10 | 2013-09-05 | Rubicon Research Private Limited | Sustained release compositions |
| US9339478B2 (en) * | 2011-02-04 | 2016-05-17 | Reckitt Benckiser Llc | Pharmaceutical formulation |
| US8287903B2 (en) * | 2011-02-15 | 2012-10-16 | Tris Pharma Inc | Orally effective methylphenidate extended release powder and aqueous suspension product |
| EP2508174A1 (en) * | 2011-04-06 | 2012-10-10 | Ljiljana Sovic Brkicic | Pharmaceutical composition |
| US20130004586A1 (en) * | 2011-06-24 | 2013-01-03 | Vachon David J | Biologically Efficacious Compositions, Articles of Manufacture and Processes for Producing and/or Using Same |
| WO2013003622A1 (en) | 2011-06-28 | 2013-01-03 | Neos Therapeutics, Lp | Dosage forms for oral administration and methods of treatment using the same |
| CA2880456A1 (en) | 2012-08-15 | 2014-02-20 | Tris Pharma, Inc. | Methylphenidate extended release chewable tablet |
| US20140122120A1 (en) * | 2012-10-30 | 2014-05-01 | Pacesetter, Inc. | Systems and methods for providing photo-based patient verification for use with implantable medical device programmers |
| ES2792082T3 (es) | 2013-02-28 | 2020-11-10 | Pf Consumer Healthcare 1 Llc | Estabilidad mejorada de composiciones líquidas novedosas |
| US10154971B2 (en) | 2013-06-17 | 2018-12-18 | Adamas Pharma, Llc | Methods of administering amantadine |
| WO2016001937A2 (en) * | 2014-06-30 | 2016-01-07 | Rubicon Research Private Limited | Modified release pharmaceutical preparations |
| CA2962950A1 (en) * | 2014-10-01 | 2016-04-07 | Crop Enhancement, Inc. | Agrochemical resinates for agricultural applications |
| US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
| MX2018013410A (es) * | 2016-05-03 | 2019-06-06 | Spectrix Therapeutics Llc | Composiciones y metodos para proporcionar la hormona tiroidea o analogos de la misma. |
| CA3072764A1 (en) | 2017-08-24 | 2019-02-28 | Adamas Pharma, Llc | Amantadine compositions, preparations thereof, and methods of use |
| US12458592B1 (en) | 2017-09-24 | 2025-11-04 | Tris Pharma, Inc. | Extended release amphetamine tablets |
| US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
| IL311303B1 (en) | 2017-10-09 | 2026-01-01 | Rhodes Pharmaceuticals Lp | Medicinal resin components and methods for their production and use |
| WO2019094292A1 (en) * | 2017-11-09 | 2019-05-16 | Spectrix Therapeutics, LLC | Compositions and methods of providing thyroid hormone of analogs thereof |
| WO2019126216A1 (en) | 2017-12-18 | 2019-06-27 | Tris Phama, Inc. | Pharmaceutical compositions comprising a floating interpenetrating polymer network forming system |
| EP3737353A1 (en) | 2017-12-18 | 2020-11-18 | Tris Pharma, Inc. | Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system |
| US11337919B2 (en) | 2017-12-18 | 2022-05-24 | Tris Pharma, Inc. | Modified release drug powder composition comprising gastro-retentive RAFT forming systems having trigger pulse drug release |
| WO2019126214A1 (en) | 2017-12-18 | 2019-06-27 | Tris Pharma, Inc. | Pharmaceutical composition comprising ghb gastro-retentive raft forming systems having trigger pulse drug release |
| WO2024163966A1 (en) | 2023-02-03 | 2024-08-08 | Tris Pharma, Inc. | Low sodium oxybate once nightly composition |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK79841C (da) * | 1952-08-04 | 1955-09-12 | Behringwerke Ag | Fremgangsmåde til fremstilling af stabile γ-globulinpræparater. |
| US3173876A (en) * | 1960-05-27 | 1965-03-16 | John C Zobrist | Cleaning methods and compositions |
| US3276586A (en) * | 1963-08-30 | 1966-10-04 | Rosaen Filter Co | Indicating means for fluid filters |
| US3546142A (en) * | 1967-01-19 | 1970-12-08 | Amicon Corp | Polyelectrolyte structures |
| US3541006A (en) * | 1968-07-03 | 1970-11-17 | Amicon Corp | Ultrafiltration process |
| US3541005A (en) * | 1969-02-05 | 1970-11-17 | Amicon Corp | Continuous ultrafiltration of macromolecular solutions |
| US4285987A (en) * | 1978-10-23 | 1981-08-25 | Alza Corporation | Process for manufacturing device with dispersion zone |
| US4221778A (en) * | 1979-01-08 | 1980-09-09 | Pennwalt Corporation | Prolonged release pharmaceutical preparations |
| AU565487B2 (en) * | 1983-09-16 | 1987-09-17 | Fisons Corporation | Liquid prolonged release pharmaceutical formulations containing ionic constituents |
| US4762709A (en) * | 1983-09-16 | 1988-08-09 | Pennwalt Corporation | Liquid prolonged release pharmaceutical formulations containing ionic constituents |
| US4692462A (en) * | 1985-03-18 | 1987-09-08 | Menley & James Laboratories, Ltd. | Compositions and method of controlling transdermal penetration of topical and systemic agents |
| US4999189A (en) * | 1988-11-14 | 1991-03-12 | Schering Corporation | Sustained release oral suspensions |
| GB9005498D0 (en) * | 1990-03-12 | 1990-05-09 | Beecham Group Plc | Composition |
| JP3207494B2 (ja) * | 1992-04-02 | 2001-09-10 | ロート製薬株式会社 | 水性懸濁製剤 |
| SE505146C2 (sv) * | 1995-10-19 | 1997-06-30 | Biogram Ab | Partiklar för fördröjd frisättning |
| US5980945A (en) * | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| US5980882A (en) * | 1997-04-16 | 1999-11-09 | Medeva Pharmaceuticals Manufacturing | Drug-resin complexes stabilized by chelating agents |
| US6613358B2 (en) * | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| US7815937B2 (en) * | 1998-10-27 | 2010-10-19 | Biovail Laboratories International Srl | Quick dissolve compositions and tablets based thereon |
| EP1250937B1 (en) * | 2001-04-09 | 2009-05-13 | Rohm And Haas Company | Controlled dissolution of active ingredients |
| JP4808405B2 (ja) * | 2002-11-26 | 2011-11-02 | ホ−レンベック ギャリ− ア−ル | 高度に水溶性の電解質薬剤のための水性徐放性ドラッグデリバリーシステム |
| US20050232987A1 (en) * | 2004-03-12 | 2005-10-20 | Viswanathan Srinivasan | Dosage form containing a morphine derivative and another drug |
| WO2007001300A1 (en) * | 2005-06-28 | 2007-01-04 | Ucb, S.A. | Multiple active drug-resin conjugate |
| US20070092553A1 (en) * | 2005-10-21 | 2007-04-26 | Pfab Lp | Compositions and methods of making rapidly dissolving lonically masked formulations |
-
2008
- 2008-05-30 CA CA2689101A patent/CA2689101C/en active Active
- 2008-05-30 MX MX2009013019A patent/MX2009013019A/es not_active Application Discontinuation
- 2008-05-30 JP JP2010510531A patent/JP2010529040A/ja active Pending
- 2008-05-30 WO PCT/US2008/065408 patent/WO2008151071A1/en not_active Ceased
- 2008-05-30 US US12/130,762 patent/US8313770B2/en active Active
- 2008-05-30 EP EP08769926.0A patent/EP2164631A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010529040A5 (https=) | ||
| Halder et al. | Entrapment efficiency and release characteristics of polyethyleneimine-treated or-untreated calcium alginate beads loaded with propranolol–resin complex | |
| Manzano et al. | Drug delivery from ordered mesoporous matrices | |
| Jono et al. | A review of particulate design for pharmaceutical powders and their production by spouted bed coating | |
| Chandrawati et al. | Engineering advanced capsosomes: maximizing the number of subcompartments, cargo retention, and temperature-triggered reaction | |
| Martins et al. | Insulin-loaded alginate microspheres for oral delivery–effect of polysaccharide reinforcement on physicochemical properties and release profile | |
| Li et al. | Progress on preparation of pH/temperature‐sensitive intelligent hydrogels and applications in target transport and controlled release of drugs | |
| Zhong et al. | Halloysite tubes as nanocontainers for herbicide and its controlled release in biodegradable poly (vinyl alcohol)/starch film | |
| Manjanna et al. | Microencapsulation: an acclaimed novel drug-delivery system for NSAIDs in arthritis | |
| Chen et al. | Programmable permeability of metal–phenolic network microcapsules | |
| US20040126427A1 (en) | Extended release dosage forms of propranolol hydrochloride | |
| WO2002017888A2 (en) | Controlled and sustained release properties of polyelectrolyte multilayer capsules | |
| Yuksel et al. | Molecularly imprinted polymers: preparation, characterisation, and application in drug delivery systems | |
| CN102579357B (zh) | 一种磁性复合载药微球及其制备方法 | |
| Criado-Gonzalez et al. | Photoresponsive nanometer-scale iron alginate hydrogels: a study of gel–sol transition using a quartz crystal microbalance | |
| Zelikin et al. | Poly (Methacrylic Acid) Polymer Hydrogel Capsules: Drug Carriers, Sub‐compartmentalized Microreactors, Artificial Organelles | |
| Yang et al. | Biomimetic silica nanocapsules for tunable sustained release and cargo protection | |
| Gupta et al. | An overview on polymethacrylate polymers in gastroretentive dosage forms | |
| Chong et al. | Tuning the permeability of polymer hydrogel capsules: An investigation of cross-linking density, membrane thickness, and cross-linkers | |
| Dhole et al. | A review on floating multiparticulate drug delivery system: a novel approach to gastric retention | |
| Kitayama et al. | pH-Responsive Capsule Polymer Particles Prepared by Interfacial Photo-Cross-Linking: Effect of the Alkyl Chain Length of the pH-Responsive Monomer | |
| Gandhi et al. | Chronopharmaceutics: as a clinically relevant drug delivery system | |
| Nivethaa et al. | Chitosan and chitosan based nanocomposites for applications as a drug delivery carrier: A review | |
| Mustafin | Interpolymer combinations of chemically complementary grades of Eudragit copolymers: a new direction in the design of peroral solid dosage forms of drug delivery systems with controlled release | |
| Jacobs et al. | Polymer delivery systems concepts |